Tempus Expands Collaboration with Moderna and Merck to Support Individualized Cancer Therapy Delivery
Individualized cancer therapies require an individualized delivery process.
Tempus, Moderna, and Merck have expanded their multiyear collaboration to support preparations for the potential commercialization of intismeran autogene, an investigational individualized neoantigen therapy being evaluated with KEYTRUDA® (pembrolizumab).
The collaboration includes the collection and transfer of tumor tissue and blood samples for next-generation sequencing. It illustrates the coordination needed to connect diagnostics, development, and manufacturing as personalized therapies advance.
For life sciences leadership teams, building that infrastructure is part of moving scientific potential toward patient impact.
